Enanta Pharmaceuticals (ENTA) News Today $15.52 +0.19 (+1.24%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 18, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 9.1%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 3,010,000 shares, a growth of 9.1% from the June 15th total of 2,760,000 shares. Based on an average daily trading volume, of 164,700 shares, the short-interest ratio is presently 18.3 days. Approximately 15.3% of the company's stock are sold short.July 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Scott T. Rottinghaus Sells 5,375 SharesJuly 16, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Scott T. Rottinghaus Sells 4,299 SharesJuly 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $64,785.93 in StockJune 18, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $89,589.78 in StockJune 17, 2024 | marketbeat.comTara Lynn Kieffer Sells 7,266 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) insider Tara Lynn Kieffer sold 7,266 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $12.33, for a total transaction of $89,589.78. Following the transaction, the insider now owns 32,341 shares of the company's stock, valued at approximately $398,764.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.June 9, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Hold" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two havMay 29, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the Jefferies Global Healthcare ConferenceMay 10, 2024 | marketbeat.comQ3 2024 EPS Estimates for Enanta Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now anticipates that the bMay 9, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasted to Post Q1 2025 Earnings of ($1.15) Per ShareEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Enanta Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings per share of ($1.15) forMay 9, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | markets.businessinsider.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionMay 7, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC WainwrightHC Wainwright dropped their price objective on Enanta Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | chron.comEnanta Pharmaceuticals: Fiscal Q2 Earnings SnapshotMay 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst ExpectationsMay 6, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETMay 5, 2024 | msn.comEnanta Pharma Q2 2024 Earnings PreviewMay 5, 2024 | markets.businessinsider.comEnanta Pharmaceuticals is about to announce its earnings — here's what to expectMay 3, 2024 | finance.yahoo.comStrong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year lossMay 1, 2024 | marketbeat.comFederated Hermes Inc. Acquires New Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Federated Hermes Inc. acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 133,189 shares of the biotechnology company's stock,April 30, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA) Scheduled to Post Earnings on MondayEnanta Pharmaceuticals (NASDAQ:ENTA) will be releasing earnings after the market closes on Monday, May 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591144)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerApril 29, 2024 | businesswire.comEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024April 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024April 15, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. lessened its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,660,520 shares of the bApril 2, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Significant Growth in Short InterestEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,410,000 shares, a growth of 15.3% from the February 29th total of 2,090,000 shares. Currently, 12.3% of the company's shares are sold short. Based on an average daily trading volume, of 263,300 shares, the days-to-cover ratio is currently 9.2 days.March 29, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.comStockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday.March 19, 2024 | money.usnews.comEnanta Pharmaceuticals IncMarch 19, 2024 | marketbeat.comWalleye Capital LLC Acquires 92,410 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Walleye Capital LLC grew its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 342.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 119,364 shares of the biotechnology company's stock after buying an additionaMarch 13, 2024 | seekingalpha.comENTA Enanta Pharmaceuticals, Inc.March 11, 2024 | finance.yahoo.comENTA Oct 2024 20.000 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 22.500 callMarch 11, 2024 | finance.yahoo.comENTA Oct 2024 10.000 putMarch 6, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 20.1%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 2,210,000 shares, a growth of 20.1% from the January 31st total of 1,840,000 shares. Based on an average daily trading volume, of 270,700 shares, the days-to-cover ratio is currently 8.2 days. Currently, 11.2% of the shares of the company are sold short.March 4, 2024 | marketbeat.comTrexquant Investment LP Takes Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Trexquant Investment LP bought a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 132,561 shares of the biotechnology company'February 24, 2024 | marketbeat.comJanney Montgomery Scott LLC Buys New Shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Janney Montgomery Scott LLC purchased a new stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 62,452 shares of the biotechnology comFebruary 23, 2024 | marketbeat.comAcadian Asset Management LLC Buys 448,201 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Acadian Asset Management LLC boosted its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 445.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 548,782 shares of the biotechnology compaFebruary 16, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 15.7%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,840,000 shares, an increase of 15.7% from the January 15th total of 1,590,000 shares. Based on an average daily trading volume, of 283,300 shares, the days-to-cover ratio is currently 6.5 days. Currently, 9.3% of the company's stock are sold short.February 12, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportFebruary 9, 2024 | markets.businessinsider.comOppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)February 9, 2024 | markets.businessinsider.comMaintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline PotentialFebruary 9, 2024 | marketbeat.comBank of New York Mellon Corp Has $1.21 Million Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Bank of New York Mellon Corp reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 34.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,955 shares of the biotechnology co Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.930.62▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼12▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GNFT News Today RLAY News Today ARQT News Today IRON News Today COLL News Today NRIX News Today BCYC News Today CNTA News Today ANAB News Today CRON News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.